Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Free energy landscape (FEL) analysis for the SP domain of native PC and its mutant structures over 200 ns MD simulation times. by Mahvash Farajzadeh-Dehkordi (17468232)

Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018. by Getachew Ossabo Babore (10788843)

Inflammatory conditions decrease CD36 expression and CD36-mediated <i>Pf</i>PEs phagocytosis through downregulation of PPARγ. by David Olagnier (205583)

Predicted targets of miR-337-3p decrease in mRNA expression on over-expression of miR-337-3p. by Liqin Du (158175)

“…<p>(A) Expression levels of miR-337-3p after 72 h transfection of NCI-H1155 cells with 50 nM miR-337-3p mimic as measured by qRT-PCR. …”

Mean and standard deviation values for the Impulse during the first 50 ms of stance (Imp50) during running shod (SH) and barefoot (BF), in both PRE and POST training, where (<sup>a... by Ana Paula da Silva Azevedo (3373688)

Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line. by Benedikt B. Kaufer (341018)

E₅₀ values of angle. by Junxia Zhou (14381598)